IBOV 172,060.43 ▲ 0.42% IPC MEX 72,419.39 ▲ 0.73% MERVAL 2,848,945 — — USD/BRL5.58— 0.00% USD/MXN18.63▲ 0.15% USD/CLP982.08▼ 0.22% USD/COP3,279▼ 0.85% USD/PEN3.41▼ 0.02% USD/ARS1,544▼ 0.03% USD/UYU40.52▲ 3.32% USD/PYG6,174▲ 1.84% USD/BOB11.63▲ 0.92% USD/DOP60.48▲ 0.05% USD/CRC446.01▲ 1.66% USD/GTQ7.64▲ 3.18% USD/HNL26.90▲ 3.29% USD/NIO36.62▲ 2.73% USD/VES902.19▲ 0.19% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.49▲ 2.41% USD/TTD6.72▲ 2.22% EUR/BRL6.18▼ 0.77% BRENT 93.28 ▲ 0.56% WTI 86.90 ▲ 0.43% IRON ORE 161.91 — — COPPER 6.21 ▼ 0.96% GOLD 3,966 ▼ 0.87% SILVER 51.11 ▼ 1.50% SOY 1,226 ▼ 0.22% CORN 448.00 — 0.00% WHEAT 600.00 ▲ 0.08% COFFEE 265.45 ▼ 2.19% SUGAR 18.47 ▲ 2.10% ORANGE JUICE 146.60 ▼ 0.10% COTTON 82.35 ▲ 4.65% COCOA 5,061 ▲ 6.73% BEEF 218.98 ▼ 0.10% CATTLE 327.80 ▼ 0.77% LITHIUM 61.07 ▲ 1.82% PETR4 43.55 ▼ 3.11% VALE3 64.43 ▼ 0.57% ITUB4 41.72 ▲ 1.26% BBDC4 14.33 ▼ 1.44% ABEV3 15.85 ▲ 0.38% BBAS3 16.89 ▼ 1.23% B3SA3 14.80 ▲ 2.21% WEGE3 51.61 ▲ 1.30% PRIO3 61.47 ▲ 2.42% SUZB3 53.80 ▼ 1.21% RENT3 30.24 ▲ 1.51% AZZA3 15.37 ▲ 4.34% CSAN3 3.03 ▲ 13.06% RAIZ4 0.30 ▼ 98.60% PCAR3 2.54 ▼ 0.78% GMAT3 4.08 ▲ 7.09% PSSA3 45.98 ▼ 1.48% CVCB3 0.86 — 0.00% POSI3 3.32 ▲ 5.40% SLCE3 17.05 ▼ 0.23% NATU3 5.62 ▲ 1.26% BRKM5 2.92 — 0.00% RANI3 8.39 ▼ 0.71% CSNA3 4.52 ▲ 3.20% IBOV 172,060.43 ▲ 0.42% IPC MEX 72,419.39 ▲ 0.73% MERVAL 2,848,945 — — USD/BRL 5.58 ▲ 0.00% USD/MXN 18.63 ▲ 0.14% USD/CLP 982.08 ▼ 0.22% USD/COP 3,279 ▼ 0.85% USD/PEN 3.41 ▼ 0.02% USD/ARS 1,544 ▼ 0.03% USD/UYU 40.52 ▲ 3.32% USD/PYG 6,174 ▲ 3.14% USD/BOB 11.63 ▲ 0.92% USD/DOP 60.48 ▲ 0.05% USD/CRC 446.01 ▲ 1.79% USD/GTQ 7.64 ▲ 3.16% USD/HNL 26.90 ▲ 3.29% USD/NIO 36.62 ▲ 2.73% USD/VES 902.19 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.49 ▲ 2.41% USD/TTD 6.72 ▲ 2.22% EUR/BRL 6.18 ▼ 0.75% BRENT 93.28 ▲ 0.56% WTI 86.90 ▲ 0.43% IRON ORE 161.91 — — COPPER 6.21 ▼ 0.96% GOLD 3,966 ▼ 0.87% SILVER 51.11 ▼ 1.50% SOY 1,226 ▼ 0.22% CORN 448.00 — 0.00% WHEAT 600.00 ▲ 0.08% COFFEE 265.45 ▼ 2.19% SUGAR 18.47 ▲ 2.10% ORANGE JUICE 146.60 ▼ 0.10% COTTON 82.35 ▲ 4.65% COCOA 5,061 ▲ 6.73% BEEF 218.98 ▼ 0.10% CATTLE 327.80 ▼ 0.77% LITHIUM 61.07 ▲ 1.82% PETR4 43.55 ▼ 3.11% VALE3 64.43 ▼ 0.57% ITUB4 41.72 ▲ 1.26% BBDC4 14.33 ▼ 1.44% ABEV3 15.85 ▲ 0.38% BBAS3 16.89 ▼ 1.23% B3SA3 14.80 ▲ 2.21% WEGE3 51.61 ▲ 1.30% PRIO3 61.47 ▲ 2.42% SUZB3 53.80 ▼ 1.21% RENT3 30.24 ▲ 1.51% AZZA3 15.37 ▲ 4.34% CSAN3 3.03 ▲ 13.06% RAIZ4 0.30 ▼ 98.60% PCAR3 2.54 ▼ 0.78% GMAT3 4.08 ▲ 7.09% PSSA3 45.98 ▼ 1.48% CVCB3 0.86 — 0.00% POSI3 3.32 ▲ 5.40% SLCE3 17.05 ▼ 0.23% NATU3 5.62 ▲ 1.26% BRKM5 2.92 — 0.00% RANI3 8.39 ▼ 0.71% CSNA3 4.52 ▲ 3.20%
since 2009
Thursday, November 12, 2026

Covid-19 Brazil

Moderna announces that coronavirus variant vaccine is ready for testing

By · · 2 min read

RIO DE JANEIRO, BRAZIL – Moderna said Wednesday, February 24th, that it has completed the initial batch of doses of a new covid-19 vaccine designed to better protect against the new South African variant, which has shown some resistance to the company’s original immunizer.

The company said it has sent the new vaccines to the National Institutes of Health (NIH) to conduct the first human trial, which could begin within weeks.

naom_5fc4e55fcf120

RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

The new vaccine is designed to better match the virus variant first detected in South Africa, but which has since spread to other areas. Moderna may be the first manufacturer to complete the lab work of designing a vaccine targeting these variants, which began spreading rapidly last year.

Other companies, including Pfizer and Johnson & Johnson, have said they are upgrading their immunizers or working on boosters that better match variants. Earlier vaccines don’t seem to perform as well against the strain identified in South Africa, and new variants may also emerge.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Petrobras to pay shareholders US$2.7 billion”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

People who have been administered two doses of the original Moderna vaccine will be given the new shot, and researchers will monitor the safety of the immunizer and its ability to induce an immune response to the new variant. Should the trial results be positive, Moderna will seek US regulatory clearance for the new vaccine, which could happen in the third quarter, CEO Stephane Bancel said in an interview. “Moderna will continue to chase these variants until the pandemic is fully under control,” Bancel said.

After the announcement, Moderna’s shares surged on the New York futures markets, and at 7:44 PM (EST) they were up 5.32%.

Source: Noticias ao Minuto

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.